"The cancer diagnostics industry is on the cusp of substantial growth, attributed to an aging population"
BioSpectrum Asia|BioSpectrum Asia Dec 2023
eadquartered in California, USA, Harae Dx, H a medical diagnostics company is all set to introduce the next generation Artificial Intelligence AI) enabled automated multi-cancer early detection system in India, China and the US in three years-time period. Harae Dx has already secured seed funding from global investor SOSV and is in the process of securing Series A funding of 12 million. The company holds strategic patents in its core technology platform, and the development and manufacturing of the entire diagnostics system will be executed through strategic partnerships using an outsourced model. In an exclusive interview with BioSpectrum Dr Nitin Malekar, Director, Harae Dx Inc., shared his views on the effectiveness of the new technologies being offered and regulatory challenges. Edited excerpts;
Bhagwati Prasad
"The cancer diagnostics industry is on the cusp of substantial growth, attributed to an aging population"

What are the new technologies you are offering? 

Our game-changing, non-invasive, portable rapid cancer diagnostic system delivers reliable test results in just 30 minutes. The heart of our innovation lies in a multi-application platform, harnessing proprietary lab-in-the-box centrifugal microfluidic technology, expressly designed for the early and precise detection of an extensive array of protein and genetic biomarkers present in blood, each pertinent to various cancer types.

Harae Dx Corp.’s visionary project overcomes the inadequacies that have plagued traditional cancer screening methodologies. First and foremost, it offers a safe, non-invasive, and cost-effective alternative, abolishing the need for cumbersome procedures that often invoke anxiety and discomfort.

Secondly, our system incorporates AI-powered algorithms that have demonstrated unparalleled accuracy, dramatically reducing the prevalence of false positives and negatives that have plagued conventional screenings.

Moreover, our solution is not just cutting-edge; it’s accessible and scalable, ensuring that a broader population can benefit from the tremendous advantages of early detection. In doing so, it has the potential to save countless lives.

The Harae Dx System is more than just a medical innovation; it’s a catalyst for transformative change in cancer care. It offers the essential tools to bridge existing healthcare gaps, making mainstream and portable cancer diagnostics the new standard. Physicians, hospitals, and laboratories now have a dependable ally, enhancing decision-making, diagnostic efficiency, and screening accuracy, all while keeping costs at a minimum.

Denne historien er fra BioSpectrum Asia Dec 2023-utgaven av BioSpectrum Asia.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

Denne historien er fra BioSpectrum Asia Dec 2023-utgaven av BioSpectrum Asia.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

FLERE HISTORIER FRA BIOSPECTRUM ASIASe alt
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
BioSpectrum Asia

Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time

US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
BioSpectrum Asia

Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers

Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine
BioSpectrum Asia

Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine

Eppendorf has announced the launch of a CO2 incubator shaker with integrated 180 °C sterilisation routine.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis
BioSpectrum Asia

Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis

US-based Waters Corporation has introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LCMS) analysis.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Singapore designs novel gene therapy offering hope for epilepsy patients
BioSpectrum Asia

Singapore designs novel gene therapy offering hope for epilepsy patients

Researchers from the Yong Loo Lin School of Medicine, National University of Singapore are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Spider venom heart drug moves to clinical trials in Australia
BioSpectrum Asia

Spider venom heart drug moves to clinical trials in Australia

A University of Queensland (UQ)-led project in Australia to develop the first-ever drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF).

time-read
1 min  |
BioSpectrum Asia Nov 2024
India develops portable ultrasound scanner for sports injury diagnosis
BioSpectrum Asia

India develops portable ultrasound scanner for sports injury diagnosis

A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-CareUltrasound (POCUS) Scanner for sports injury diagnosis and management.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Integris appoints medtech veteran Probir Das as new CEO
BioSpectrum Asia

Integris appoints medtech veteran Probir Das as new CEO

Integris Healthcare, a global diversified medical technology company, has announced the appointment of Probir Das as Chief Executive Officer (CEO). He will join effective November 2024 and will be based in New Delhi.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Clarity Pharma promotes Michelle Parker to CEO
BioSpectrum Asia

Clarity Pharma promotes Michelle Parker to CEO

Australia-based Clarity Pharmaceuticals has announced the appointment of Michelle Parker as Chief Executive Officer (CEO), effective from October 11, 2024.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Dr Makoto Sugita steps in as President of Nxera Pharma Japan
BioSpectrum Asia

Dr Makoto Sugita steps in as President of Nxera Pharma Japan

Nxera Pharma Co., formerly known as Sosei Group or Sosei Heptares, has announced the appointment of Dr Makoto Sugita, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer (CMO) of Nxera Pharma.

time-read
1 min  |
BioSpectrum Asia Nov 2024